# Payers cover off-label combinations only inside registry-randomised trials

Source: https://onco.cc/ideas/idea-tr2-payer-combo-cwe/  
OnCo record `idea-tr2-payer-combo-cwe` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Insurers already pay for off-label drug combinations that have never been randomised. Paying only when the patient joins a registry-based randomised comparison, as Medicare did for devices and the Cancer Drugs Fund did for cancer drugs, would turn that spending into evidence at no new drug cost.

## Summary

Coverage with evidence development has been used by Medicare for devices and by NICE for cancer drugs through the Cancer Drugs Fund. Applying it to off-label combinations would fund a large pragmatic randomised programme with no new drug costs, since the drugs would be paid for anyway, and would end reimbursement of combinations that fail.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: A coverage-with-evidence programme for off-label combinations will randomise at least 5,000 patients per year in one large payer and produce a definitive result for at least two combinations within four years.
- Rationale: The Cancer Drugs Fund's managed access showed payers can collect evidence as a condition of payment; randomisation is the missing step.
- Proposed test: Pilot with one payer and two common off-label combinations with documented equipoise; measure enrolment, cost neutrality and time to answer.
- Maturity: speculative
- Actor: payer

## Sources

- Bottleneck evidence (Too many combinations to test): Palmer & Sorger, Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy (Cell 2017): https://doi.org/10.1016/j.cell.2017.11.009

## Connected records

- ideas: [Pay for new biomarker tests only while evidence of clinical utility is being collected](https://onco.cc/ideas/idea-tr2-biomarker-cwe/), [Record what happens when doctors use cancer drugs off-label](https://onco.cc/ideas/idea-tr2-off-label-outcome-registry/), [Registry-embedded randomisation of treatment order in routine care](https://onco.cc/ideas/idea-tr2-pragmatic-sequence-randomisation/)
- terms: [Real-world evidence](https://onco.cc/terms/real-world-evidence/)
- bottlenecks: [Prices and value](https://onco.cc/bottlenecks/b-drug-pricing/), [Too many combinations to test](https://onco.cc/bottlenecks/b-combination-space/)
- key papers: [Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy](https://onco.cc/key-papers/paper-palmer-cell/)

---
JSON: https://onco.cc/api/v1/entities/idea-tr2-payer-combo-cwe.json